Clinical Trials Logo

Prostatic Neoplasms clinical trials

View clinical trials related to Prostatic Neoplasms.

Filter by:

NCT ID: NCT05478694 Recruiting - Prostate Cancer Clinical Trials

Outcomes of Focal Ablation for Prostate Cancer

Start date: February 1, 2023
Phase:
Study type: Observational

This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.

NCT ID: NCT05478239 Recruiting - Prostate Cancer Clinical Trials

ArtemiCoffee in Patients With Rising PSA

Start date: August 11, 2023
Phase: Phase 2
Study type: Interventional

Until now, clinicians have been challenged to improve the treatment of biochemically recurrent (BCR) prostate cancer in which prostatic specific antigen (PSA) rises without radiological or clinical progression years after localized treatment (radical prostatectomy or radiation therapy) with or without hormonal treatment. Approximately 50-90% of men with high-risk prostate cancer will experience a BCR. Artesunate has demonstrated anti-tumor activity in both in vivo and in vitro cell lines. It is hypothesized that Artemisia annua (Aa) coffee has the potential to decrease rising PSA among patients with biochemical recurrence of prostate cancer.

NCT ID: NCT05477823 Recruiting - Prostate Cancer Clinical Trials

Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer

Start date: March 8, 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to evaluate the imaging and gene expression biomarkers in prostate cancer. Participants have high-risk prostate cancer and have indicated they will undergo external beam radiation therapy, brachytherapy, and androgen deprivation therapy (EBRT+BTX+ADT). Participants can expect to be in this study for up to 5 years.

NCT ID: NCT05471414 Recruiting - Prostate Cancer Clinical Trials

Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer

WFPBD
Start date: September 22, 2022
Phase: N/A
Study type: Interventional

The study is comparing the effect on weight of providing home-delivered whole-food, plant-based meals versus standard, general nutritional counseling to men with prostate cancer on androgen-deprivation therapy (ADT).

NCT ID: NCT05471128 Recruiting - Prostate Cancer Clinical Trials

MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy

OU-SCC-PROBX
Start date: January 27, 2023
Phase:
Study type: Observational

The purpose of this study is to find out how best to detect clinically significant lesions of prostate cancer by using micro-ultrasound technology (ExactVu) and by multiparametric magnetic-resonance imaging (mpMRI).

NCT ID: NCT05470036 Recruiting - Prostate Cancer Clinical Trials

Improving Germline Testing in At-Risk Patients With Prostate Cancer

IMPRINT
Start date: September 27, 2022
Phase: N/A
Study type: Interventional

A quality improvement initiative to improve rates of germline testing among men with prostate cancer through the use of an in-clinic educational session.

NCT ID: NCT05469269 Recruiting - Prostate Cancer Clinical Trials

Cleveland African American Prostate Cancer Project

Start date: June 9, 2023
Phase: N/A
Study type: Interventional

The purpose of this research is to test intervention strategies that encourage and support Black or African American men who are 40 and older to complete prostate cancer screening, and specifically to complete a prostate-specific antigen (PSA) test.

NCT ID: NCT05467176 Recruiting - Prostate Cancer Clinical Trials

A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

OPTYX
Start date: October 4, 2022
Phase:
Study type: Observational

This is a multi-center, prospective, observational study of patients being treated with ORGOVYX. The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer in routine clinical care and the clinical course during treatment with and following cessation of ORGOVYX.

NCT ID: NCT05461261 Recruiting - Chemotherapy Effect Clinical Trials

The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer

Start date: July 1, 2022
Phase: Phase 2
Study type: Interventional

This randomized controlled trial was designed to evaluate the efficacy and safety of Docetaxel combined with Platinum-based drugs compared with Docetaxel alone for metastatic hormone-sensitive prostate cancer patients carrying DNA repair mutation.

NCT ID: NCT05458544 Recruiting - Clinical trials for Metastatic Castration-resistant Prostate Cancer

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application

LUCIDA
Start date: September 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1: The objective of the Phase 1 part of the clinical trial is to verify safety and tolerability (dose-limiting toxicity [DLT], maximum tolerated dose [MTD]) of a single 3.7 Giga-Becquerel (GBq) dose with the potential for one dose level de-escalation to 2.775 GBq if necessary, to determine the recommended [177Lu]Ludotadipep dose for use in the Phase 2a part of the trial. Phase 2a: The objective of the Phase 2a part of the trial is to evaluate safety and efficacy for repeated administration of the recommended [177Lu]Ludotadipep dose. The Recommended Phase 2 dose (RP2D) will be based on the study results from the Phase 1 trial in South Korea upon consultation with the FDA.